Jefferies Group’s AC Immune ACIU Stock Holding History

Jefferies Group’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-728,575	Closed	-$6.41M	–	2290
2017 Q2	$6.41M	Sell	728,575 -5,525	-0.8%	-$51.2K	0.04%	424
2017 Q1	$7.61M	Buy	+734,100	New	+$9.01M	0.06%	345

Other funds holding ACIU

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BAM

Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

LBC

Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return

Jefferies Group's ACIU Position: Q3 2017 in Review

Jefferies Group sold out of AC Immune (ACIU) in Q3 2017, closing a stake of 728,575 shares — an estimated $6.41M sold.

Jefferies Group first reported a position in ACIU in Q1 2017 and held it in 2 quarters. The position peaked at $7.61M in Q1 2017. 15 funds tracked by Wall St. Rank hold ACIU as of Q3 2017.

Jefferies Group reported no remaining AC Immune position as of Q3 2017 after selling out during the quarter.
Jefferies Group sold 728,575 AC Immune shares in Q3 2017, an estimated $6.41M.
Jefferies Group first reported a position in AC Immune in Q1 2017 and held it in 2 quarters.
Jefferies Group's AC Immune position peaked at $7.61M in Q1 2017.
15 funds tracked by Wall St. Rank held AC Immune as of Q3 2017.

Based on Jefferies Group's 13F filing for Q3 2017, filed 14 Nov 2017.